Erasca, Inc. (ERAS) Stock Competitors & Peer Comparison
See (ERAS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ERAS | $11.97 | -9.80% | 3.7B | -12.87 | -$0.93 | N/A |
| NVO | $42.96 | -1.81% | 190.8B | 10.06 | $4.27 | +4.19% |
| VRTX | $446.83 | +1.15% | 113.4B | 26.55 | $16.83 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $635.45 | +1.07% | 65.5B | 15.51 | $40.97 | +0.57% |
| ARGX | $891.32 | +5.82% | 55.2B | 39.56 | $22.53 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $303.05 | -0.19% | 40.5B | 76.14 | $3.98 | N/A |
| RVMD | $149.23 | -4.15% | 31.7B | -20.99 | -$7.11 | N/A |
| RPRX | $55.87 | +1.54% | 24B | 29.41 | $1.90 | +1.63% |
Stock Comparison
ERAS vs NVO Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, NVO has a market cap of 190.8B. Regarding current trading prices, ERAS is priced at $11.97, while NVO trades at $42.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas NVO's P/E ratio is 10.06. In terms of profitability, ERAS's ROE is -0.77%, compared to NVO's ROE of +0.66%. Regarding short-term risk, ERAS is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check NVO's competition here
ERAS vs VRTX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, VRTX has a market cap of 113.4B. Regarding current trading prices, ERAS is priced at $11.97, while VRTX trades at $446.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas VRTX's P/E ratio is 26.55. In terms of profitability, ERAS's ROE is -0.77%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ERAS is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check VRTX's competition here
ERAS vs VRNA Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ERAS is priced at $11.97, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ERAS's ROE is -0.77%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, ERAS is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check VRNA's competition here
ERAS vs REGN Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, REGN has a market cap of 65.5B. Regarding current trading prices, ERAS is priced at $11.97, while REGN trades at $635.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas REGN's P/E ratio is 15.51. In terms of profitability, ERAS's ROE is -0.77%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ERAS is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check REGN's competition here
ERAS vs ARGX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, ARGX has a market cap of 55.2B. Regarding current trading prices, ERAS is priced at $11.97, while ARGX trades at $891.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas ARGX's P/E ratio is 39.56. In terms of profitability, ERAS's ROE is -0.77%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, ERAS is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ARGX's competition here
ERAS vs SGEN Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ERAS is priced at $11.97, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ERAS's ROE is -0.77%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ERAS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check SGEN's competition here
ERAS vs ALNY Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, ALNY has a market cap of 40.5B. Regarding current trading prices, ERAS is priced at $11.97, while ALNY trades at $303.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas ALNY's P/E ratio is 76.14. In terms of profitability, ERAS's ROE is -0.77%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ERAS is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ALNY's competition here
ERAS vs RVMD Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, RVMD has a market cap of 31.7B. Regarding current trading prices, ERAS is priced at $11.97, while RVMD trades at $149.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas RVMD's P/E ratio is -20.99. In terms of profitability, ERAS's ROE is -0.77%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ERAS is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RVMD's competition here
ERAS vs RPRX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, RPRX has a market cap of 24B. Regarding current trading prices, ERAS is priced at $11.97, while RPRX trades at $55.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas RPRX's P/E ratio is 29.41. In terms of profitability, ERAS's ROE is -0.77%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, ERAS is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RPRX's competition here
ERAS vs UTHR Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, UTHR has a market cap of 23.3B. Regarding current trading prices, ERAS is priced at $11.97, while UTHR trades at $549.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas UTHR's P/E ratio is 20.33. In terms of profitability, ERAS's ROE is -0.77%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ERAS is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check UTHR's competition here
ERAS vs BNTX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, BNTX has a market cap of 22.3B. Regarding current trading prices, ERAS is priced at $11.97, while BNTX trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas BNTX's P/E ratio is -14.90. In terms of profitability, ERAS's ROE is -0.77%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ERAS is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check BNTX's competition here
ERAS vs ROIV Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, ROIV has a market cap of 20.6B. Regarding current trading prices, ERAS is priced at $11.97, while ROIV trades at $28.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas ROIV's P/E ratio is -52.93. In terms of profitability, ERAS's ROE is -0.77%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ERAS is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ROIV's competition here
ERAS vs INCY Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, INCY has a market cap of 20.5B. Regarding current trading prices, ERAS is priced at $11.97, while INCY trades at $102.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas INCY's P/E ratio is 14.46. In terms of profitability, ERAS's ROE is -0.77%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ERAS is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check INCY's competition here
ERAS vs INSM Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, INSM has a market cap of 20.4B. Regarding current trading prices, ERAS is priced at $11.97, while INSM trades at $94.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas INSM's P/E ratio is -16.36. In terms of profitability, ERAS's ROE is -0.77%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ERAS is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for ERAS.Check INSM's competition here
ERAS vs BGNE Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ERAS is priced at $11.97, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ERAS's ROE is -0.77%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ERAS is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check BGNE's competition here
ERAS vs MRNA Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, MRNA has a market cap of 18.8B. Regarding current trading prices, ERAS is priced at $11.97, while MRNA trades at $47.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas MRNA's P/E ratio is -5.83. In terms of profitability, ERAS's ROE is -0.77%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ERAS is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check MRNA's competition here
ERAS vs DNA-WT Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ERAS is priced at $11.97, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ERAS's ROE is -0.77%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ERAS is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check DNA-WT's competition here
ERAS vs NBIX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, NBIX has a market cap of 16.5B. Regarding current trading prices, ERAS is priced at $11.97, while NBIX trades at $163.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas NBIX's P/E ratio is 25.21. In terms of profitability, ERAS's ROE is -0.77%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ERAS is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check NBIX's competition here
ERAS vs GMAB Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, GMAB has a market cap of 15.4B. Regarding current trading prices, ERAS is priced at $11.97, while GMAB trades at $25.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas GMAB's P/E ratio is 19.05. In terms of profitability, ERAS's ROE is -0.77%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ERAS is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check GMAB's competition here
ERAS vs JAZZ Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, JAZZ has a market cap of 15B. Regarding current trading prices, ERAS is priced at $11.97, while JAZZ trades at $238.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas JAZZ's P/E ratio is 2168.82. In terms of profitability, ERAS's ROE is -0.77%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ERAS is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check JAZZ's competition here
ERAS vs EXEL Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, EXEL has a market cap of 13.2B. Regarding current trading prices, ERAS is priced at $11.97, while EXEL trades at $52.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas EXEL's P/E ratio is 17.45. In terms of profitability, ERAS's ROE is -0.77%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ERAS is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check EXEL's competition here
ERAS vs BBIO Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, ERAS is priced at $11.97, while BBIO trades at $67.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas BBIO's P/E ratio is -18.08. In terms of profitability, ERAS's ROE is -0.77%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ERAS is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check BBIO's competition here
ERAS vs ASND Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, ASND has a market cap of 13B. Regarding current trading prices, ERAS is priced at $11.97, while ASND trades at $210.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas ASND's P/E ratio is 23.91. In terms of profitability, ERAS's ROE is -0.77%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ERAS is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ASND's competition here
ERAS vs KRTX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ERAS is priced at $11.97, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ERAS's ROE is -0.77%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ERAS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check KRTX's competition here
ERAS vs IONS Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, IONS has a market cap of 12.3B. Regarding current trading prices, ERAS is priced at $11.97, while IONS trades at $74.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas IONS's P/E ratio is -37.05. In terms of profitability, ERAS's ROE is -0.77%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ERAS is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check IONS's competition here
ERAS vs AXSM Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, AXSM has a market cap of 12B. Regarding current trading prices, ERAS is priced at $11.97, while AXSM trades at $232.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas AXSM's P/E ratio is -62.62. In terms of profitability, ERAS's ROE is -0.77%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ERAS is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check AXSM's competition here
ERAS vs SMMT Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, SMMT has a market cap of 11.5B. Regarding current trading prices, ERAS is priced at $11.97, while SMMT trades at $14.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas SMMT's P/E ratio is -9.29. In terms of profitability, ERAS's ROE is -0.77%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ERAS is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check SMMT's competition here
ERAS vs RNAM Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ERAS is priced at $11.97, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ERAS's ROE is -0.77%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ERAS is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RNAM's competition here
ERAS vs MDGL Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, MDGL has a market cap of 11.2B. Regarding current trading prices, ERAS is priced at $11.97, while MDGL trades at $486.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas MDGL's P/E ratio is -36.07. In terms of profitability, ERAS's ROE is -0.77%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ERAS is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check MDGL's competition here
ERAS vs BMRN Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, ERAS is priced at $11.97, while BMRN trades at $56.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas BMRN's P/E ratio is 40.84. In terms of profitability, ERAS's ROE is -0.77%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ERAS is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check BMRN's competition here
ERAS vs ARWR Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, ARWR has a market cap of 10.3B. Regarding current trading prices, ERAS is priced at $11.97, while ARWR trades at $73.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas ARWR's P/E ratio is -32.20. In terms of profitability, ERAS's ROE is -0.77%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ERAS is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ARWR's competition here
ERAS vs RXDX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ERAS is priced at $11.97, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ERAS's ROE is -0.77%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ERAS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RXDX's competition here
ERAS vs CYTK Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, CYTK has a market cap of 8.9B. Regarding current trading prices, ERAS is priced at $11.97, while CYTK trades at $71.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas CYTK's P/E ratio is -10.44. In terms of profitability, ERAS's ROE is -0.77%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ERAS is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CYTK's competition here
ERAS vs KRYS Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, KRYS has a market cap of 8.9B. Regarding current trading prices, ERAS is priced at $11.97, while KRYS trades at $301.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas KRYS's P/E ratio is 40.24. In terms of profitability, ERAS's ROE is -0.77%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ERAS is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check KRYS's competition here
ERAS vs IMGN Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ERAS is priced at $11.97, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ERAS's ROE is -0.77%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ERAS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check IMGN's competition here
ERAS vs HALO Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, HALO has a market cap of 8.5B. Regarding current trading prices, ERAS is priced at $11.97, while HALO trades at $71.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas HALO's P/E ratio is 25.10. In terms of profitability, ERAS's ROE is -0.77%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ERAS is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check HALO's competition here
ERAS vs BPMC Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ERAS is priced at $11.97, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ERAS's ROE is -0.77%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, ERAS is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check BPMC's competition here
ERAS vs CERE Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ERAS is priced at $11.97, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas CERE's P/E ratio is -16.47. In terms of profitability, ERAS's ROE is -0.77%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ERAS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CERE's competition here
ERAS vs TECH Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, TECH has a market cap of 8.1B. Regarding current trading prices, ERAS is priced at $11.97, while TECH trades at $51.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas TECH's P/E ratio is 74.27. In terms of profitability, ERAS's ROE is -0.77%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ERAS is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check TECH's competition here
ERAS vs CORT Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, CORT has a market cap of 7.8B. Regarding current trading prices, ERAS is priced at $11.97, while CORT trades at $72.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas CORT's P/E ratio is 207.49. In terms of profitability, ERAS's ROE is -0.77%, compared to CORT's ROE of +0.08%. Regarding short-term risk, ERAS is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CORT's competition here
ERAS vs MTSR Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ERAS is priced at $11.97, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ERAS's ROE is -0.77%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ERAS is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check MTSR's competition here
ERAS vs IBRX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, IBRX has a market cap of 7.2B. Regarding current trading prices, ERAS is priced at $11.97, while IBRX trades at $6.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas IBRX's P/E ratio is -8.14. In terms of profitability, ERAS's ROE is -0.77%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ERAS is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check IBRX's competition here
ERAS vs ALKS Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, ALKS has a market cap of 7.1B. Regarding current trading prices, ERAS is priced at $11.97, while ALKS trades at $42.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas ALKS's P/E ratio is 47.56. In terms of profitability, ERAS's ROE is -0.77%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ERAS is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ALKS's competition here
ERAS vs PCVX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, PCVX has a market cap of 6.8B. Regarding current trading prices, ERAS is priced at $11.97, while PCVX trades at $47.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas PCVX's P/E ratio is -6.87. In terms of profitability, ERAS's ROE is -0.77%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ERAS is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check PCVX's competition here
ERAS vs MRUS Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ERAS is priced at $11.97, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ERAS's ROE is -0.77%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ERAS is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check MRUS's competition here
ERAS vs ACLX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ERAS is priced at $11.97, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ERAS's ROE is -0.77%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ERAS is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ACLX's competition here
ERAS vs NUVL Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, NUVL has a market cap of 6.7B. Regarding current trading prices, ERAS is priced at $11.97, while NUVL trades at $90.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas NUVL's P/E ratio is -15.01. In terms of profitability, ERAS's ROE is -0.77%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ERAS is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check NUVL's competition here
ERAS vs ABVX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, ABVX has a market cap of 6.7B. Regarding current trading prices, ERAS is priced at $11.97, while ABVX trades at $101.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas ABVX's P/E ratio is -18.98. In terms of profitability, ERAS's ROE is -0.77%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ERAS is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ABVX's competition here
ERAS vs RETA Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ERAS is priced at $11.97, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas RETA's P/E ratio is -66.29. In terms of profitability, ERAS's ROE is -0.77%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ERAS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RETA's competition here
ERAS vs IMVT Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, IMVT has a market cap of 6.4B. Regarding current trading prices, ERAS is priced at $11.97, while IMVT trades at $31.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas IMVT's P/E ratio is -11.23. In terms of profitability, ERAS's ROE is -0.77%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ERAS is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check IMVT's competition here
ERAS vs PTGX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, PTGX has a market cap of 6.3B. Regarding current trading prices, ERAS is priced at $11.97, while PTGX trades at $97.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas PTGX's P/E ratio is -53.80. In terms of profitability, ERAS's ROE is -0.77%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ERAS is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check PTGX's competition here
ERAS vs TGTX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, TGTX has a market cap of 6.1B. Regarding current trading prices, ERAS is priced at $11.97, while TGTX trades at $40.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas TGTX's P/E ratio is 14.04. In terms of profitability, ERAS's ROE is -0.77%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ERAS is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check TGTX's competition here
ERAS vs CNTA Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, ERAS is priced at $11.97, while CNTA trades at $39.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas CNTA's P/E ratio is -22.26. In terms of profitability, ERAS's ROE is -0.77%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ERAS is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CNTA's competition here
ERAS vs KYMR Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, KYMR has a market cap of 6.1B. Regarding current trading prices, ERAS is priced at $11.97, while KYMR trades at $74.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas KYMR's P/E ratio is -20.71. In terms of profitability, ERAS's ROE is -0.77%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ERAS is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check KYMR's competition here
ERAS vs LEGN Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, LEGN has a market cap of 6B. Regarding current trading prices, ERAS is priced at $11.97, while LEGN trades at $32.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas LEGN's P/E ratio is -23.64. In terms of profitability, ERAS's ROE is -0.77%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ERAS is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check LEGN's competition here
ERAS vs RYTM Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, ERAS is priced at $11.97, while RYTM trades at $86.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas RYTM's P/E ratio is -27.60. In terms of profitability, ERAS's ROE is -0.77%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ERAS is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RYTM's competition here
ERAS vs PTCT Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, ERAS is priced at $11.97, while PTCT trades at $70.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas PTCT's P/E ratio is -27.94. In terms of profitability, ERAS's ROE is -0.77%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ERAS is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check PTCT's competition here
ERAS vs BLTE Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, BLTE has a market cap of 5.7B. Regarding current trading prices, ERAS is priced at $11.97, while BLTE trades at $143.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas BLTE's P/E ratio is -56.44. In terms of profitability, ERAS's ROE is -0.77%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, ERAS is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check BLTE's competition here
ERAS vs CDTX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ERAS is priced at $11.97, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ERAS's ROE is -0.77%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ERAS is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CDTX's competition here
ERAS vs ABCM Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ERAS is priced at $11.97, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ERAS's ROE is -0.77%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ERAS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ABCM's competition here
ERAS vs ISEE Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ERAS is priced at $11.97, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ERAS's ROE is -0.77%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ERAS is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ISEE's competition here
ERAS vs LQDA Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, LQDA has a market cap of 5.5B. Regarding current trading prices, ERAS is priced at $11.97, while LQDA trades at $61.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas LQDA's P/E ratio is 363.82. In terms of profitability, ERAS's ROE is -0.77%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, ERAS is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check LQDA's competition here
ERAS vs APGE Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, APGE has a market cap of 5.4B. Regarding current trading prices, ERAS is priced at $11.97, while APGE trades at $86.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas APGE's P/E ratio is -20.07. In terms of profitability, ERAS's ROE is -0.77%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ERAS is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check APGE's competition here
ERAS vs PRAX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, PRAX has a market cap of 5.4B. Regarding current trading prices, ERAS is priced at $11.97, while PRAX trades at $254.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas PRAX's P/E ratio is -18.96. In terms of profitability, ERAS's ROE is -0.77%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ERAS is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check PRAX's competition here
ERAS vs SRRK Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, ERAS is priced at $11.97, while SRRK trades at $44.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas SRRK's P/E ratio is -12.84. In terms of profitability, ERAS's ROE is -0.77%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ERAS is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check SRRK's competition here
ERAS vs COGT Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, COGT has a market cap of 5.3B. Regarding current trading prices, ERAS is priced at $11.97, while COGT trades at $31.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas COGT's P/E ratio is -14.29. In terms of profitability, ERAS's ROE is -0.77%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ERAS is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check COGT's competition here
ERAS vs FBIOX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, ERAS is priced at $11.97, while FBIOX trades at $24.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ERAS's ROE is -0.77%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ERAS is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check FBIOX's competition here
ERAS vs APLS Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ERAS is priced at $11.97, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas APLS's P/E ratio is 38.35. In terms of profitability, ERAS's ROE is -0.77%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ERAS is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check APLS's competition here
ERAS vs CRSP Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, ERAS is priced at $11.97, while CRSP trades at $51.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas CRSP's P/E ratio is -8.40. In terms of profitability, ERAS's ROE is -0.77%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ERAS is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CRSP's competition here
ERAS vs TERN Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ERAS is priced at $11.97, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas TERN's P/E ratio is -51.41. In terms of profitability, ERAS's ROE is -0.77%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ERAS is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check TERN's competition here
ERAS vs LGND Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, LGND has a market cap of 4.7B. Regarding current trading prices, ERAS is priced at $11.97, while LGND trades at $237.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas LGND's P/E ratio is 30.94. In terms of profitability, ERAS's ROE is -0.77%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ERAS is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check LGND's competition here
ERAS vs CGON Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, CGON has a market cap of 4.7B. Regarding current trading prices, ERAS is priced at $11.97, while CGON trades at $53.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas CGON's P/E ratio is -22.96. In terms of profitability, ERAS's ROE is -0.77%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ERAS is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CGON's competition here
ERAS vs MIRM Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, ERAS is priced at $11.97, while MIRM trades at $93.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas MIRM's P/E ratio is -6.87. In terms of profitability, ERAS's ROE is -0.77%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ERAS is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check MIRM's competition here
ERAS vs CAI Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, ERAS is priced at $11.97, while CAI trades at $16.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas CAI's P/E ratio is -5.97. In terms of profitability, ERAS's ROE is -0.77%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ERAS is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CAI's competition here
ERAS vs FOLD Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ERAS is priced at $11.97, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ERAS's ROE is -0.77%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ERAS is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check FOLD's competition here
ERAS vs AKRO Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ERAS is priced at $11.97, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ERAS's ROE is -0.77%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ERAS is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check AKRO's competition here
ERAS vs ALPN Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ERAS is priced at $11.97, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ERAS's ROE is -0.77%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ERAS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ALPN's competition here
ERAS vs SYRE Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, ERAS is priced at $11.97, while SYRE trades at $73.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas SYRE's P/E ratio is -34.74. In terms of profitability, ERAS's ROE is -0.77%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ERAS is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check SYRE's competition here
ERAS vs CELC Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, ERAS is priced at $11.97, while CELC trades at $88.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas CELC's P/E ratio is -22.64. In terms of profitability, ERAS's ROE is -0.77%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ERAS is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CELC's competition here
ERAS vs TVTX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, TVTX has a market cap of 4.3B. Regarding current trading prices, ERAS is priced at $11.97, while TVTX trades at $45.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas TVTX's P/E ratio is -91.58. In terms of profitability, ERAS's ROE is -0.77%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ERAS is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check TVTX's competition here
ERAS vs OPT Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ERAS is priced at $11.97, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas OPT's P/E ratio is -1.52. In terms of profitability, ERAS's ROE is -0.77%, compared to OPT's ROE of +1.09%. Regarding short-term risk, ERAS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check OPT's competition here
ERAS vs MRTX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ERAS is priced at $11.97, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ERAS's ROE is -0.77%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ERAS is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check MRTX's competition here
ERAS vs XENE Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, XENE has a market cap of 4.1B. Regarding current trading prices, ERAS is priced at $11.97, while XENE trades at $51.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas XENE's P/E ratio is -11.01. In terms of profitability, ERAS's ROE is -0.77%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ERAS is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check XENE's competition here
ERAS vs VCYT Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, VCYT has a market cap of 3.9B. Regarding current trading prices, ERAS is priced at $11.97, while VCYT trades at $48.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas VCYT's P/E ratio is 45.12. In terms of profitability, ERAS's ROE is -0.77%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, ERAS is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check VCYT's competition here
ERAS vs EWTX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, EWTX has a market cap of 3.8B. Regarding current trading prices, ERAS is priced at $11.97, while EWTX trades at $35.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas EWTX's P/E ratio is -21.44. In terms of profitability, ERAS's ROE is -0.77%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ERAS is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check EWTX's competition here
ERAS vs CPRX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, ERAS is priced at $11.97, while CPRX trades at $31.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas CPRX's P/E ratio is 18.08. In terms of profitability, ERAS's ROE is -0.77%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ERAS is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CPRX's competition here
ERAS vs MANE Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, MANE has a market cap of 3.8B. Regarding current trading prices, ERAS is priced at $11.97, while MANE trades at $91.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas MANE's P/E ratio is -34.44. In terms of profitability, ERAS's ROE is -0.77%, compared to MANE's ROE of -0.95%. Regarding short-term risk, ERAS is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for ERAS.Check MANE's competition here
ERAS vs RYZB Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ERAS is priced at $11.97, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ERAS's ROE is -0.77%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ERAS is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RYZB's competition here
ERAS vs CBAY Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ERAS is priced at $11.97, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ERAS's ROE is -0.77%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ERAS is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CBAY's competition here
ERAS vs ACAD Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, ERAS is priced at $11.97, while ACAD trades at $21.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas ACAD's P/E ratio is 9.76. In terms of profitability, ERAS's ROE is -0.77%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ERAS is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ACAD's competition here
ERAS vs NAMS Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, ERAS is priced at $11.97, while NAMS trades at $31.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas NAMS's P/E ratio is -17.71. In terms of profitability, ERAS's ROE is -0.77%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ERAS is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check NAMS's competition here
ERAS vs KNSA Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, ERAS is priced at $11.97, while KNSA trades at $48.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas KNSA's P/E ratio is 53.21. In terms of profitability, ERAS's ROE is -0.77%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, ERAS is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check KNSA's competition here
ERAS vs SWTX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ERAS is priced at $11.97, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ERAS's ROE is -0.77%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, ERAS is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check SWTX's competition here
ERAS vs CRNX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, CRNX has a market cap of 3.5B. Regarding current trading prices, ERAS is priced at $11.97, while CRNX trades at $32.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas CRNX's P/E ratio is -6.40. In terms of profitability, ERAS's ROE is -0.77%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ERAS is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CRNX's competition here
ERAS vs DNTH Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, DNTH has a market cap of 3.4B. Regarding current trading prices, ERAS is priced at $11.97, while DNTH trades at $80.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas DNTH's P/E ratio is -19.03. In terms of profitability, ERAS's ROE is -0.77%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ERAS is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check DNTH's competition here
ERAS vs VKTX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, VKTX has a market cap of 3.3B. Regarding current trading prices, ERAS is priced at $11.97, while VKTX trades at $28.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas VKTX's P/E ratio is -6.86. In terms of profitability, ERAS's ROE is -0.77%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ERAS is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check VKTX's competition here
ERAS vs TLX Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, ERAS is priced at $11.97, while TLX trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas TLX's P/E ratio is -465.00. In terms of profitability, ERAS's ROE is -0.77%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ERAS is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check TLX's competition here
ERAS vs DNLI Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, ERAS is priced at $11.97, while DNLI trades at $19.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas DNLI's P/E ratio is -6.78. In terms of profitability, ERAS's ROE is -0.77%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ERAS is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check DNLI's competition here
ERAS vs BEAM Comparison June 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 3.7B. In comparison, BEAM has a market cap of 3B. Regarding current trading prices, ERAS is priced at $11.97, while BEAM trades at $29.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -12.87, whereas BEAM's P/E ratio is -60.00. In terms of profitability, ERAS's ROE is -0.77%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, ERAS is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for ERAS.Check BEAM's competition here